Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Physiol ; 236(2): 1054-1067, 2021 02.
Article in English | MEDLINE | ID: mdl-32617972

ABSTRACT

Mesenchymal stem cells (MSCs) have a great potential in regenerative medicine because of their multipotential and immunoregulatory capacities, while in early pregnancy they could participate in the immunotolerance of the mother towards the embryo. Peripheral blood constitutes an accessible source of MSCs. We successfully isolated peripheral blood MSC (pbMSCs) lines, with or without previous bone marrow mobilization. All pbMSCs lines obtained in both conditions presented classical MSC markers and properties, alkaline phosphatase activity and multipotent capacity to differentiate among adipogenic, osteogenic or chondrogenic lineages, and suppressed the proliferation of T cells. pbMSCs showed migratory capacity without cytokine stimulation while increasing their migration rate in the presence of inflammatory or embryo implantation stimuli. Interestingly, in contrast to MSCs derived from endometrial tissue, three pbMSCs lines also showed increased migration towards the IFN-τ implantation cytokine. Moreover, the secretome produced by an early implantation stage embryonic trophectoderm cell line showed a chemoattractant effect in pbMSCs. Our results suggest that circulating MSCs are present in the peripheral blood under healthy conditions. The fact that both the inflammation and implantation signals induced pbMSCs chemotaxis highlights MSC heterogeneity and suggests that their migratory capacity may differ according to their tissue of origin and would suggest the possible active recruitment of MSCs from bone marrow during pregnancy to repress the immune response to prevent the embryo rejection by the maternal organism.


Subject(s)
Chemotaxis/genetics , Inflammation/genetics , Mesenchymal Stem Cells/metabolism , Regenerative Medicine , Adipogenesis/genetics , Animals , Cattle , Cell Differentiation/genetics , Cell Proliferation/genetics , Cells, Cultured , Chondrogenesis/genetics , Embryo Implantation/genetics , Female , Humans , Inflammation/pathology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Maternal-Fetal Relations/physiology , Mesenchymal Stem Cells/physiology , Osteogenesis/genetics
2.
J Nephrol ; 34(3): 861-874, 2021 06.
Article in English | MEDLINE | ID: mdl-33275196

ABSTRACT

BACKGROUND: In kidney transplantation, fibrosis represents the final and irreversible consequence of the pathogenic mechanisms that lead to graft failure, and in the late stages it irremediably precedes the loss of renal function. The invasiveness of kidney biopsy prevents this condition from being frequently monitored, while clinical data are rather unspecific. The objective of this study was to find noninvasive biomarkers of kidney rejection. METHODS: We carried out proteomic analysis of the urinary Extracellular Vesicles (uEVs) from a cohort of kidney transplant recipients (n = 23) classified according to their biopsy-based diagnosis and clinical parameters as interstitial fibrosis and tubular atrophy (IFTA), acute cellular rejection (ACR), calcineurin inhibitors toxicity (CNIT) and normal kidney function (NKF). RESULTS: Shotgun mass spectrometry of uEV-proteins identified differential expression of several proteins among these different groups. Up to 23 of these proteins were re-evaluated using targeted proteomics in a new independent cohort of patients (n = 41) classified in the same diagnostic groups. Among other results, we found a differential expression of vitronectin (VTN) in patients displaying chronic interstitial and tubular lesions (ci and ct mean > 2 according to Banff criteria). These results were further confirmed by a pilot study using enzyme-linked immunosorbent assay (ELISA). CONCLUSION: Urinary vitronectin levels are a potential stand-alone biomarker to monitor fibrotic changes in kidney transplant recipients in a non-invasive fashion.


Subject(s)
Kidney Transplantation , Kidney/pathology , Vitronectin , Atrophy/pathology , Biomarkers/urine , Biopsy , Female , Fibrosis , Graft Rejection/pathology , Graft Rejection/urine , Humans , Male , Middle Aged , Pilot Projects , Proteomics , Vitronectin/urine
3.
Int J Mol Sci ; 21(20)2020 Oct 14.
Article in English | MEDLINE | ID: mdl-33066346

ABSTRACT

Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic CNI toxicity (CNIT) may lead to kidney fibrosis, a threatening scenario for graft survival. However, there is still controversy regarding CNIT diagnosis, monitoring and therapeutic management, and their specific effects at the molecular level are not fully known. Aiming to better characterize CNIT patients, in the present study, we collected urine from kidney-transplanted patients treated with CNI who (i) had a normal kidney function, (ii) suffered CNIT, or (iii) presented interstitial fibrosis and tubular atrophy (IFTA). Urinary extracellular vesicles (uEV) were enriched and the proteome was analyzed to get insight into changes happening during CNI. Members of the uroplakin and plakin families were significantly upregulated in the CNIT group, suggesting an important role in CNIT processes. Although biomarkers cannot be asserted from this single pilot study, our results evidence the potential of uEV as a source of non-invasive protein biomarkers for a better detection and monitoring of this renal alteration in kidney-transplanted patients.


Subject(s)
Calcineurin Inhibitors/pharmacology , Extracellular Vesicles/metabolism , Kidney Diseases/prevention & control , Kidney Transplantation/adverse effects , Proteome/metabolism , Adult , Aged , Biomarkers/urine , Calcineurin Inhibitors/therapeutic use , Cyclosporine/pharmacology , Cyclosporine/therapeutic use , Female , Fibrosis , Graft Survival , Humans , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Kidney Diseases/etiology , Kidney Transplantation/methods , Male , Middle Aged , Plakins/urine , Proteome/genetics , Tacrolimus/pharmacology , Tacrolimus/therapeutic use , Uroplakins/urine
4.
Stem Cell Res Ther ; 10(1): 356, 2019 11 28.
Article in English | MEDLINE | ID: mdl-31779673

ABSTRACT

BACKGROUND: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton's jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. METHODS: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFß1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. RESULTS: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. CONCLUSIONS: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.


Subject(s)
Bone Marrow Cells/metabolism , Cell Differentiation , Mesenchymal Stem Cells/metabolism , Osteogenesis , Bone Marrow Cells/cytology , Bone Morphogenetic Protein 2/metabolism , Culture Media, Conditioned/pharmacology , Humans , Mesenchymal Stem Cells/cytology , Proteomics , Real-Time Polymerase Chain Reaction
5.
Front Immunol ; 10: 2413, 2019.
Article in English | MEDLINE | ID: mdl-31660058

ABSTRACT

[This corrects the article DOI: 10.3389/fimmu.2019.01288.].

6.
Front Immunol ; 10: 1288, 2019.
Article in English | MEDLINE | ID: mdl-31244839

ABSTRACT

Mesenchymal stem or stromal cells (MSC) have proven immunomodulatory properties toward B cell activation and induce regulatory B cells (Breg), through a dual mechanism of action that relies both on cell contact and secreted factors. One of them are MSC-derived extracellular vesicles (EVs), membrane nanovesicles that mediate cell communication and typically reflect the phenotype of the cell of origin. MSC-EVs could resemble MSC functions, and are being contemplated as an improved alternative to the MSC-based immunomodulatory therapy. In the present work, we focused on the factors secreted by MSC and aimed to elucidate the putative role of MSC-EVs in the immunomodulation of B cells. EVs and soluble protein-enriched fractions (PF) were isolated from MSC-conditioned medium (CM) using size-exclusion chromatography (SEC) and their capacity to modulate B cell activation, induction of Breg and B cell proliferation was compared to that of the whole MSCs. Co-culture with MSC or unfractionated CM induced naïve and CD24hiCD38hi, IL-10 producing (Breg) phenotypes on B cells while not affecting proliferation. MSC-PF had a comparable effect to MSCs, inducing a naïve phenotype, and even though they did not induce the shift toward a CD24hiCD38hi population, MSC-PF fostered IL-10 production by B cells. Conversely, MSC-EVs failed to promote naïve B cells and to reduce memory B cells. MSC-EVs induced CD24hiCD38hi B cells to a similar extent of that of MSC, but not bona fide Bregs since they did not produce IL-10. Our results show that B cell modulation by MSC is partially mediated by soluble factors other than EVs.

7.
Stem Cell Res Ther ; 10(1): 23, 2019 01 11.
Article in English | MEDLINE | ID: mdl-30635057

ABSTRACT

BACKGROUND: The uterus is a histologically dynamic organ, and the mechanisms coordinating its regeneration during the oestrous cycle and implantation are poorly understood. The aim of this study was to isolate, immortalize and characterize bovine endometrial mesenchymal stem cell (eMSC) lines from different oestrous cycle stages (embryo in the oviduct, embryo in the uterus or absence of embryo) and examine their migratory and immunomodulatory properties in an inflammatory or implantation-like environment, as well as possible changes in cell transdifferentiation. METHODS: eMSCs were isolated and analysed in terms of morphological features, expression of cell surface and intracellular markers of pluripotency, inmunocytochemical analyses, alkaline phosphatase activity, proliferation and osteogenic or chondrogenic differentiation capacities, as well as their ability to migrate in response to inflammatory (TNF-α or IL-1ß) or implantation (IFN-τ) cytokines and their immunomodulatory effect in the proliferation of T cells. RESULTS: All eMSCs showed MSC properties such as adherence to plastic, high proliferative capacity, expression of CD44 and vimentin, undetectable expression of CD34 or MHCII, positivity for Pou5F1 and alkaline phosphatase activity. In the absence of an embryo, eMSC showed an apparent mesenchymal to epithelial transition state. eMSC during the entire oestrous cycle differentiated to osteogenic or chondrogenic lineages, showed the ability to suppress T cell proliferation and showed migratory capacity towards pro-inflammatory signal, while responded with a block in their migration to the embryo-derived pregnancy signal. CONCLUSION: This study describes for the first time the isolation, immortalization and characterization of bovine mesenchymal stem cell lines from different oestrous cycle stages, with a clear mesenchymal pattern and immunomodulatory properties. Our study also reports that the migratory capacity of the eMSC was increased towards an inflammatory niche but was reduced in response to the expression of implantation cytokine by the embryo. The combination of both signals (pro-inflammatory and implantation) would ensure the retention of eMSC in case of pregnancy, to ensure the immunomodulation necessary in the mother for embryo survival. In addition, in the absence of an embryo, eMSC showed an apparent mesenchymal to epithelial transition state.


Subject(s)
Cell Differentiation/genetics , Chondrogenesis/genetics , Mesenchymal Stem Cells/cytology , Osteogenesis/genetics , Animals , Cattle , Cell Proliferation/genetics , Endometrium/cytology , Epithelial-Mesenchymal Transition/genetics , Female , Luteolysis/genetics , Mesenchymal Stem Cells/metabolism , Stem Cell Niche/genetics , Tropism/genetics
8.
PLoS One ; 12(5): e0176987, 2017.
Article in English | MEDLINE | ID: mdl-28489901

ABSTRACT

Peritoneal Dialysis (PD) is considered the best option for a cost-effective mid-term dialysis in patients with Chronic Renal Failure. However, functional failure of the peritoneal membrane (PM) force many patients to stop PD treatment and start haemodialysis. Currently, PM functionality is monitored by the peritoneal equilibration test, a tedious technique that often show changes when the membrane damage is advanced. As in other pathologies, the identification and characterization of extracellular vesicles (EVs) in the peritoneal dialysis efflux (PDE) may represent a non-invasive alternative to identify biomarkers of membrane failure. Using size-exclusion chromatography, we isolated EVs from PDE in a group of patients. Vesicles were characterized by the presence of tetraspanin markers, nanoparticle tracking analysis profile, cryo-electron microscopy and mass spectrometry. Here, we report the isolation and characterization of PDE-EVs. Based on mass spectrometry, we have found a set of well-conserved proteins among patients. Interestingly, the peptide profile also revealed remarkable changes between newly enrolled and longer-treated PD patients. These results are the first step to the identification of PDE-EVs based new markers of PM damage, which could support clinicians in their decision-making in a non-invasive manner.


Subject(s)
Extracellular Vesicles/pathology , Peritoneal Dialysis , Peritoneum/pathology , Proteome/analysis , Proteomics , Adult , Aged , Biomarkers/analysis , Biomarkers/metabolism , Extracellular Vesicles/metabolism , Female , Humans , Male , Middle Aged , Peritoneal Dialysis/methods , Peritoneum/metabolism , Proteome/metabolism , Proteomics/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...